GSK plc ADR Stock
GSK plc ADR Stock
A loss of -1.290% shows a downward development for GSK plc ADR.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for GSK plc ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of GSK plc ADR in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | -1.290% | 2.727% | -2.165% | 39.506% | 8.134% | 40.373% | 6.353% |
| Bayer AG ADR | 1.720% | 5.357% | -3.279% | 72.263% | 34.091% | -10.606% | -4.839% |
| Novartis AG | -1.120% | -0.383% | -1.168% | 36.150% | 14.537% | 69.200% | 69.200% |
| Novartis AG ADR | -0.720% | -0.730% | -1.449% | 36.546% | 14.768% | 42.558% | 74.359% |
Comments
GSK (GSK) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for GSK provided by MarketBeat